BeiGene's Stomach, Esophageal Cancer Drug Receives Positive European Committee Opinions

MT Newswires Live10-21

BeiGene (BGNE) said Monday that the European Medicines Agency's Committee for Medicinal Products for Human Use has issued positive opinions recommending an extended authorization for Tevimbra (tislelizumab) in gastric or gastroesophageal junction adenocarcinoma and esophageal squamous cell carcinoma.

The recommendations were based on two clinical trials showing that the drug, in combination with chemotherapy, "improved survival compared to treatment with a placebo plus chemotherapy," said Florian Lordick, director and professor of oncology at the University Cancer Center in Leipzig.

BeiGene shares were 0.5% higher in recent premarket trading.

Price: 220.00, Change: +1.03, Percent Change: +0.47

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2477852205?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-10-21 20:42","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2477852205","market":"hk","top_or_hot":-1,"title":"BeiGene's Stomach, Esophageal Cancer Drug Receives Positive European Committee Opinions","media":"MT Newswires Live","content":"<html><body><p> BeiGene (BGNE) said Monday that the European Medicines Agency's Committee for Medicinal Products for Human Use has issued positive opinions recommending an extended authorization for Tevimbra (tislelizumab) in gastric or gastroesophageal junction adenocarcinoma and esophageal squamous cell carcinoma.</p><p>The recommendations were based on two clinical trials showing that the drug, in combination with chemotherapy, \"improved survival compared to treatment with a placebo plus chemotherapy,\" said Florian Lordick, director and professor of oncology at the University Cancer Center in Leipzig.</p><p>BeiGene shares were 0.5% higher in recent premarket trading.</p><p>Price: 220.00, Change: +1.03, Percent Change: +0.47</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BeiGene's Stomach, Esophageal Cancer Drug Receives Positive European Committee Opinions</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBeiGene's Stomach, Esophageal Cancer Drug Receives Positive European Committee Opinions\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-10-21 20:42 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.mtnewswires.com/><strong>MT Newswires Live</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>BeiGene (BGNE) said Monday that the European Medicines Agency's Committee for Medicinal Products for Human Use has issued positive opinions recommending an extended authorization for Tevimbra (...</p>\n\n<a href=\"https://www.mtnewswires.com/\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU1969619763.USD","symbol_name":"EASTSPRING INV CHINA A SHARES GROWTH \"A\" (USD) ACC","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2477852205","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2477852205","pubTimestamp":1729514563,"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"BeiGene  said Monday that the European Medicines Agency's Committee for Medicinal Products for Human Use has issued positive opinions recommending an extended authorization for Tevimbra  in gastric or gastroesophageal junction adenocarcinoma and esophageal squamous cell carcinoma.The recommendations were based on two clinical trials showing that the drug, in combination with chemotherapy, \"improved survival compared to treatment with a placebo plus chemotherapy,\" said Florian Lordick, director and professor of oncology at the University Cancer Center in Leipzig.BeiGene shares were 0.5% higher in recent premarket trading.Price: 220.00, Change: +1.03, Percent Change: +0.47","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU1969619763.USD":"EASTSPRING INV CHINA A SHARES GROWTH \"A\" (USD) ACC","BK1500":"做空集合股","BK4585":"ETF&股票定投概念","BK1161":"生物科技","BK4505":"高瓴资本持仓","BGNE":"百济神州","06160":"百济神州","LU0307460666.USD":"EASTSPRING INVESTMENTS CHINA EQUITY \"A\" ACC","BK4139":"生物科技","BK4588":"碎股","BK4526":"热门中概股","BK4504":"桥水持仓","BK1583":"高瓴概念","LU2328871848.SGD":"Eastspring Investments - China A Shares Growth AS SGD","LU0588546209.SGD":"Eastspring Investments - China Equity Fund AS SGD","BK1588":"回港中概股","BK4548":"巴美列捷福持仓","BK4535":"淡马锡持仓"},"translate_title":"百济神州胃癌、食道癌药物获得欧盟委员会积极意见","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"BGNE":1,"06160":1},"content_text":"BeiGene (BGNE) said Monday that the European Medicines Agency's Committee for Medicinal Products for Human Use has issued positive opinions recommending an extended authorization for Tevimbra (tislelizumab) in gastric or gastroesophageal junction adenocarcinoma and esophageal squamous cell carcinoma.The recommendations were based on two clinical trials showing that the drug, in combination with chemotherapy, \"improved survival compared to treatment with a placebo plus chemotherapy,\" said Florian Lordick, director and professor of oncology at the University Cancer Center in Leipzig.BeiGene shares were 0.5% higher in recent premarket trading.Price: 220.00, Change: +1.03, Percent Change: +0.47","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.1","shortVersion":"4.29.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2477852205"}